Zobrazeno 1 - 10
of 65
pro vyhledávání: '"Michael Entzeroth"'
Autor:
Michael Entzeroth, Anil Kumar Ratty
Publikováno v:
Open Journal of Depression. :31-68
Over more than 60 years, monoamine oxidase (MAO) inhibitors are available for therapy of central nervous diseases. Although they have shown to be efficacious specifically in the treatment of major depressive disorders and treatment-resistant depressi
Autor:
Hong Yan Song, Melvin Ng, Zou Yong, Eric T. Sun, Michael Entzeroth, Anders Poulsen, Dizhong Chen, Kee Chuan Goh, Joyce Wei Wei Chang, Kanda Sangthongpitag, Walter Stünkel, Niefang Yu, Zahid Bonday, Haishan Wang, Weiping Deng, Lye Pek Ling, Stéphanie Blanchard, Hwee Hoon Khng, Wai Chung Ong, Lijuan Fang, Xiaofeng Wu, Xukun Wang, Siok Kun Goh
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 19:1403-1408
A series of N-hydroxy-1,2-disubstituted-1H-benzimidazol-5-yl acrylamides were designed and synthesized as novel HDAC inhibitors. General SAR has been established for the substituents at positions 1 and 2, as well as the importance of the ethylene gro
Publikováno v:
Biotechnology Journal. 3:364-369
The Experimental Therapeutics Center (ETC) has been established at Biopolis to advance translational research by bridging the gap between discovery science and commercialization. We describe the Electronic Research Habitat at ETC, a comprehensive har
Autor:
Jacobus C. A. Van Meel, Kandace M. Matzek, Horst Lehmann, Michael Entzeroth, Volker Gladigau, Thomas Ebner, Jochen Schmid, Wolfgang Wienen, Ulrich Busch, Joachim Stangier, Joan Kempthorne-Rawson, Norbert Hauel
Publikováno v:
Cardiovascular Drug Reviews. 18:127-154
Telmisartan is a potent, long-lasting, nonpeptide antagonist of the angiotensin II type-1 (AT 1 ) receptor that is indicated for the treatment of essential hypertension. It selectively and insurmountably inhibits stimulation of the AT 1 receptor by a
Autor:
Yifa Zhou, Kanda Sangthongpitag, Xukun Wang, Haishan Wang, Blanche Shamoon, Marcia L. Taylor, Michael Entzeroth, Yin Zheng, Janet Rose, BinHui Ni, Kee Chuan Goh, Ze-Yi Lim, Christoph Reinhard, Mark X. Du, Walter Stünkel, Brad Carte, Lijuan Fang, Niefang Yu, Anne B. Jefferson
Publikováno v:
Drug Development Research. 62:349-361
Polo-like kinase 1 (PLK1) has been shown to be involved in cell cycle progression of rapidly proliferating, nontransformed cells as well as tumor cells. In cancer, overexpression of PLK1 contributes to the malignant state by aberrant cell cycle regul
Autor:
Michael Entzeroth
Publikováno v:
Laboratory Automation & Information Management. 33:87-92
Autor:
Klaus-Dieter Willim, Henri Doods, Wolfgang Eberlein, Wolfgang Wienen, Michael Entzeroth, Wolfhard Engel, Klaus Rudolf, Heike A. Wieland
Publikováno v:
Regulatory Peptides. 65:71-77
Based on the assumption that the pharmacophoric groups interacting with the Y1 receptor are located in the C-terminal part of neuropeptide Y, low molecular weight compounds with high affinity and selectivity for the Y1 receptor were designed and synt
Autor:
Klaus-Dieter Willim, Henri Doods, Heike A. Wieland, Wolfgang Wienen, Wolfhard Engel, Klaus Rudolf, Hans Braunger, Michael Entzeroth, Wolfgang Eberlein
Publikováno v:
European Journal of Pharmacology. 278:239-242
The binding of tritium-labelled BIBP3226, N2-(diphenylacetyl)-N-[(4-hydroxy-phenyl)methyl]-D-arginine amide, to human neuroblastoma SK-N-MC cells was investigated. [3H]BIBP3226 reversibly binds to neuropeptide Y receptors of the Y1 subtype expressed
Publikováno v:
European Journal of Pharmacology. 253:275-281
The present study examined the effects of a series of tricyclic muscarinic receptor antagonists on muscarinic receptors present in the guinea-pig ileum, both in vitro and in vivo. The selectivity profiles of these antagonists and that of atropine wer
Autor:
Norbert Hauel, Wolfgang Wienen, Jacobus C. A. Van Meel, Berthold Narr, Kai M. Hasselbach, Uwe Ries, Helmut Wittneben, Gerhard Mihm, Michael Entzeroth
Publikováno v:
Journal of Medicinal Chemistry. 36:4040-4051
Starting from the recently reported nonpeptidic angiotensin II (AII) receptor antagonists DuP753 (1) and Exp 7711 (2), we have designed and investigated novel substituted benzimidazoles. Systemic variation of several substituents at the benzimidazole